retatrutide clinical trials phase Today, we shared new data from two 3 of retatrutide, our investigational triple agonist. Learn more at our link in bio Starting Phase 3b Clinical Trial

Specifically, prebiotic fibers like resistant starch and beta-glucan support the production of short-chain fatty acids (SCFA), which stimulate your intestinal cells to release GLP-1

Early research suggests retatrutide may be one of the most powerful weight-loss medications studied so far

This history matters because it establishes a pattern of marketing that outpaces the science

As of late August 2023, P.B

Certificate Program in Nutrition Strategies Build a strong foundation in whole-food nutrition, metabolic health, and evidence-based dietary strategies to achieve lasting health and wellness transformations However, despite its potent effects, endogenous GLP-1 has a very short half-life of just 1-2 minutes due to rapid degradation by the dipeptidyl peptidase-4 (DPP-4) enzyme